Skip to main content
SpringerLink
Log in

Reducing the risk of coronary heart disease in patients with diabetes mellitus requires a multifactorial approach

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wilson SH, Kennedy FP, Garrat KN. Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus. Drugs and Aging 2001: 18(5): 325–33

    Article  PubMed  CAS  Google Scholar 

  2. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 823–28

    Article  PubMed  CAS  Google Scholar 

  3. American Diabetes Association: Clinical Practice Recommendations 2001; 24 Suppl. 1. Available from URL: www.diabetes.org/clinicalrecommendations/caresup1Jan01.htm

  4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53

    Article  Google Scholar 

  5. British National Formulary No. 42. London: The Pharmaceutical Press, 2001 Sep

  6. Sheen AJ & Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998; 55(2): 225–36

    Article  Google Scholar 

  7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.

    Article  Google Scholar 

  8. Tight blood pressure control and risk of macro vascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317 (7160): 703-13

  9. Hansson L, Zanchetti A, Carruthers SG, Dalhof B, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351(9118): 1755–62

    Article  PubMed  CAS  Google Scholar 

  10. Hansson L, Lindholm LH, Niskanen L, et al. Principal results of the Captopril Prevention Project (CAPPP): effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet 1998; 353: 645–6

    Google Scholar 

  11. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603

    Article  PubMed  CAS  Google Scholar 

  12. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998; 98: 213–9

    Google Scholar 

  13. Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Survival Study (4S). Diabetes Care 1997; 20: 614–20

    Article  PubMed  Google Scholar 

  14. Collins R. Heart Protection Study (HPS): simvastatin and anti-oxidants [web page]. Available from: http://www.thaiheart.org/heart_protection_study.htm [Accessed 2002 Feb 5]

  15. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemifibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45

    Article  PubMed  CAS  Google Scholar 

  16. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999 Aug 5; 341(6): 410–8

    Article  PubMed  CAS  Google Scholar 

  17. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001 Mar 24; 357 (9260): 905-10.

  18. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992 Sep 9; 268 (10): 1292-300.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reducing the risk of coronary heart disease in patients with diabetes mellitus requires a multifactorial approach. Drugs Ther. Perspect 18, 6–10 (2002). https://doi.org/10.2165/00042310-200218030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218030-00003

Keywords

Search

Navigation